Renold J. Capocasale
CEO & Founder, FlowMetric
“You’re Vaccinated! Now What? COVID-19 Immune Response Testing”
After earning his undergraduate degree from Villanova University, Renold acquired more than 20 years of experience in pharmaceutical research and development, primarily as an expert in polychromatic flow cytometry, cell sorting and immunology-based assay development.
Prior to establishing FlowMetric, Renold worked for over 13 years at Centocor, a subsidiary of Johnson and Johnson. He established a state-of-the-art flow cytometry core facility at Centocor where he earned five prestigious Johnson & Johnson awards for scientific excellence and innovation, including work on the marketed compounds, Remicade® and Stelara®. Ren has authored more than 30 peer reviewed scientific manuscripts, publications and book chapters, co-authored four US Patents and has been invited to speak at numerous International Conferences.
Renold is active on several Pennsylvania-based boards, including the Board of Directors of Atrin Pharmaceuticals, Bucks County; the Board of Trustees of Neumann University, Delaware County and the Board of Directors for the not-for-profit educational institution iPraxis, supporting STEM programs for underprivileged children in the Philadelphia region. In addition, Renold is an Adjunct Professor at Drexel University College of Medicine.
Since the launching of FlowMetric back in 2010 and the expansion of the brand to include an International Division in Italy and a Diagnostic division in PA, Renold has been presented with several prestigious awards for his work in FlowMetric including: Best CRO in the Tri-State Region by the Philadelphia Business Journal and PA Bio in 2012; the Marcum Innovator of the Year for the Med-sized Biotech/Healthcare category in 2014, as well as the Best of Doylestown Award in Biotechnology Company Category by the Doylestown Award Program in 2014 and 2015. In addition, FlowMetric Europe qualified in the top 3 most innovative startups at the Bando Start-Up Expo organized by Regione Lombardia in 2015.
In addition, Renold has been actively involved in his community as and a member of the not-for-profit Sigma Xi Scientific Research Society, is an Eagle Scout and continues to dedicate time to the Boy Scouts of America as a Scout Leader of Troop 577, Dresher PA.
Ben Doranz, PhD, MBA
President & CEO, Integral Molecular
“COVID-19 Update: Variants vs. Vaccines, Who Will Win?”
Ben Doranz co-founded Integral Molecular in 2001 and has led all aspects of the company’s growth since its inception, bringing five different technologies from research to market and growing the company into a profitable commercial entity. He is an inventor on six of the company’s patents, the principal investigator on over 30 NIH grants, and an author on over 90 publications, including articles published in Cell, Science, and Nature.
Dr. Doranz is an established life science entrepreneur previously responsible for directing the biotechnology program at the Port of Technology business incubator and helping create startups at the University of Pennsylvania. Dr. Doranz earned a Ph.D. in Cellular and Molecular Biology from the University of Pennsylvania where he led the discovery of the coreceptor for HIV (CCR5), an MBA at Wharton where he co-founded the Penn Biotech Group, and a BA at Cornell University.
Director, IT & Operations
Karl Fischer is a strategic IT and Business Operations leader with a rich history of successfully positioning companies for growth, specializing on helping early-stage Biopharma companies navigate the business challenges associated with mergers & acquisitions, public offerings, commercialization, and other critical inflection points. He currently leads IT and Operations for SwanBio Therapeutics, a gene therapy company that aims to bring life-changing treatments to people with devastating, genetically defined neurological conditions.
President & Co-founder, Layer 8 Security
Kevin Hyde is an expert in establishing cybersecurity operational and governance programs for the intelligence community and private industry. He is a career field grade officer in the Marine Corps Reserve and served on active duty at the National Security Agency and U.S. Cyber Command. In addition to his technical career, Kevin has utilized his former experience as a spokesman for the Marine Corps by speaking as a cybersecurity expert on multiple panels and conducting executive trainings for various companies. He volunteers for patriotic and Christian organizations in the Greater Philadelphia area during his free time. The Philadelphia Business Journal in July 2016 honored Kevin with the designation as one of Philadelphia’s top Veterans of Influence.
Sue Dillon, PhD
Co-Founder, President and CEO, Aro Biotherapuetics
Sue Dillon is President and CEO of Aro Biotherapeutics, focused on addressing intractable diseases with tissue targeted genetic medicines. The Company was co-founded 2018, by Sue Dillon and Karyn O’Neil, Aro CSO and co-inventor of the Centyrin drug platform which is designed to achieve precise and efficient receptor mediated targeting of RNA drugs to specific tissues. The Company announced an $88M Series A financing in early 2021, and is progressing its wholly owned pipeline of Centyrin – RNA drug conjugates in orphan genetic and immune diseases into preclinical development. Additionally, Aro is collaborating with RNA drug industry leader Ionis Pharmaceuticals in a collaboration and licensing deal announced in 2020.
Previously, from 2001 through 2017 Sue held multiple leadership roles at Centocor and Janssen Research & Development, a division of Johnson & Johnson Pharmaceuticals. In 2009, Sue was appointed Global Therapeutic Area Head for immunology for Janssen, Research & Development. In this role, Sue had end-to-end responsibility for immunology small and large molecule drug discovery and all stages of clinical development of a series of blockbuster products for autoimmune diseases, including REMICADE® (infliximab), SIMPONI® (GOLIMUMAB), STELARA® (ustekinumab), and TREMFYA® (guselkumab), a first in class anti-IL-23 antibody approved in 2017.Sue earned her Ph.D. in Microbiology and Immunology from Thomas Jefferson University and completed an NIH-sponsored postdoctoral fellowship in Immunology at Duke University. Sue has published over 50 scientific articles, and is inventor on six issued patents.
In 2007, Sue was awarded the Distinguished Alumni Award from Thomas Jefferson University, and she was named one of the ‘Fierce Women in Biotech’ by Fierce Biotech in 2013. She serves as an independent Board Director of Vedanta Biosciences and as the Vice Chair of the Board of Trustees of the renowned Wistar Institute in Philadelphia.
President and CEO, Onconova Therapeutics
Dr. Fruchtman joined Onconova in January 2015 as Chief Medical Officer. He was promoted to President in July 2018 and to President & CEO in January 2019. He has extensive experience in large and small biopharmaceutical companies and has led successful clinical development programs while serving in senior positions at Ortho Biotech Products, Novartis, Allos Therapeutics, Spectrum Pharmaceuticals and Syndax Pharmaceuticals.
Previously, Dr. Fruchtman was on the faculty of the Mount Sinai School of Medicine and the Director of the Stem Cell Transplantation and Myeloproliferative Disorder Programs at Mount Sinai Hospital in New York City. He is an author of more than 170 lectures, presentations, books, chapters, and abstracts and serves as an external reviewer for multiple medical journals.
Dr. Fruchtman received his medical degree from New York Medical College with the distinction of membership in the Alpha Omega Alpha honorary medical fraternity.
President and CEO, XyloCor Therapeutics
Al Gianchetti has more than 25 years of drug development and commercialization experience, including over 10 years in the cardiovascular/metabolic therapeutic area. He has held executive level roles at GSK and additional leadership roles with small biotech and specialty pharma companies including Vanda Pharmaceutics. Mr. Gianchetti has extensive experience in both commercial strategy/operations and R&D including seven Phase III programs, over 10 Phase I/II programs and several product launches.
Valerie Arkoosh, MD, MPH
Chair, Montgomery County Board of Commissioners
Dr. Valerie Arkoosh is a parent of three, physician, health policy expert, and community leader who was appointed a Montgomery County Commissioner on January 29, 2015, elected to a full four year term on November 3, 2015 and re-elected on November 5, 2019. She has served as Chair of the Montgomery County Board of Commissioners since November 2016. A practicing obstetric anesthesiologist for over two decades, most recently at the Hospital of the University of Pennsylvania, Val has always put the health and well being of her community and local families first. As Commission Chair, Val oversees a budget of $430 million and directs more than 2,500 employees. The Commission manages human services for more than 100,000 residents, Voter Services, over 130 county bridges, 75 miles of roads and other infrastructure, 7 county parks and nearly 100 miles of trails.
Born and raised in Omaha, Nebraska, Val has a degree in Economics from Northwestern University, and attended medical school at the University of Nebraska College of Medicine. She moved to Philadelphia in 1986 for residency training at Jefferson Medical College. Val served as Chair of the Department of Anesthesiology at Drexel University College of Medicine from 1999-2004 where she successfully restored her department to fiscal solvency following the Allegheny University bankruptcy. Frustrated by watching the families she cared for fall through the cracks time and time again – Val earned a Masters Degree in Public Health from the Johns Hopkins Bloomberg School of Public Health with a concentration in Health Policy giving her the tools to increase her impact outside of the exam room. Through her many local and national leadership positions, Val has been a tireless advocate for fair and equitable treatment of all people.
Val lives in Springfield Township, Montgomery County, with her husband Jeff Harbison and their three children.
Regional Director, State and Local Government Relations, Walgreens
Bryan Lowe is the Regional Director of State and Local Government Affairs for Walgreen Co., in this role, he represents Walgreens before state and local governments in Mid-Atlantic Region (DE, MD, NJ, OH, PA, VA, and WV). Prior to this position he served as Senior Director of State Government Affairs for the Healthcare Distribution Alliance, representing members of a national trade associations before state legislatures throughout the country. Previously, Bryan was an Associate at the Harrisburg based government affairs firm, Greenlee Partners. In this capacity, Bryan represented various client interests before the Pennsylvania General Assembly. Additionally, Bryan formerly served as a Government Relations Associate for the Pennsylvania Commission for Community Colleges.
Bryan received his BA degree in Political Science from Shippensburg University in 2008, and his Masters of Public Administration, from Shippensburg in 2017. In 2018, Bryan was nominated by the Governor and confirmed by the Pennsylvania State Senate to serve on the Shippensburg University Council of Trustees. Bryan lives in Harrisburg with his wife Kristie, and daughter Tenley.
Senior Director, Manufacturer Operations, AmerisourceBergen
Chris joins us as Senior Director, Manufacturer Operations from AmerisourceBergen Drug Corporation (ABC.) Day to day, Chris is responsible for operationalizing state and federal regulatory requirements across ABC’s portfolio of businesses. Since the onset of the COVID19 pandemic, like many of his colleagues, Chris has pivoted to support ABC’s COVID19 operations. Chris currently serves as the program manager for ABC’s COVID19 Vaccine Taskforce.
Previously, Chris worked for KPMG US, LP where he served his clients as a Manager, Management Consulting. His focus was Life Science Advisory, specifically strategy and implementation related to complex regulatory requirements. Before that, Chris held several roles of increasing responsibility across Johnson & Johnson’s global supply chain.
Director, Office of Intergovernmental Affairs, Pennsylvania Department of Health
More Speaker Information Coming Soon
Sponsored & Moderated by Meredith Dante, Partner, Ballard Spahr
President & Chief Commercial Officer, Paratek Pharmaceuticals
Adam Woodrow has been President and Chief Commercial Officer since June 2019. Prior to that, he served as the CCO between October 2014 and June 2019.
Mr. Woodrow previously worked for Pfizer in various strategic and operational commercial roles leading the commercial development group in Pfizer’s Specialty Care Business Unit, launching Xeljanz® and Vyndaqel® . In addition, he led the global strategic marketing teams in a variety of fields from rare disease to acute hospital based infections.
Mr. Woodrow joined Pfizer from Wyeth, where he was VP and Global Business Manager for Enbrel leading all commercial aspects of Wyeth’s inflammation portfolio, co-promotion, licensing, and product development. At Wyeth, he held senior marketing and sales positions in the U.S. and U.K., and was responsible for the successful launches of medicines such as (Tygacil®) and (ReFacto®).
Mr. Woodrow has a BSc in Chemistry from the University of Wales College of Cardiff.
Managing Vice President, Cook MyoSite
Ryan Pruchnic earned his bachelor’s degree in biology and his master’s degree in exercise physiology from the University of Pittsburgh and his MBA from the Joseph M. Katz Graduate School of Business at the University of Pittsburgh. While working as a research scientist investigating the experimental uses of skeletal muscle-derived cells for urinary tract tissue augmentation, he was part of the original team that custom-built the cell isolation and manufacturing technology for use in human clinical trials. Ryan has authored and coauthored numerous peer-reviewed scientific journal articles and book chapters relating to gene and cell therapy research for musculoskeletal disorders. Ryan currently serves as Site Head for Cook MyoSite and is responsible for the Manufacturing and Business Administration functions of the company.
Executive Director, New Product Planning and Business Development, Cabaletta Bio
More Speaker Information Coming Soon
Sponsored & Moderated by Joe Colletti, Executive Vice President, JLL
Director of Legal and Compliance Services, MidAtlantic Employers’ Association (MEA)
Amy McAndrew is MidAtlantic Employers’ Association’s Director of Legal and Compliance Services. Amy is a highly skilled labor and employment law attorney who worked for 18 years at the Philadelphia-based law firm Pepper Hamilton LLP (now Troutman Pepper), a general practice firm with offices throughout the United States. She also spent a year with Littler Mendelson P.C., an international labor and employment law firm. Amy graduated from Rutgers College with a double major in English and Communication, where she received highest honors in Communication and was a member of Phi Beta Kappa. Amy went on to graduate cum laude from Boston College Law School.
As Director of Legal and Compliance Services at MEA, Amy provides legal advice and compliance services to the Association’s Members, in addition to providing Members with updates on developments in employment law. Amy is admitted to practice in Pennsylvania and New Jersey.
Program Director, Preferred EAP
Carolyn Lamparella is a Licensed Professional Counselor and Director of Lehigh Valley Health Network’s employee assistance program, Preferred EAP. Carolyn graduated from James Madison University with an Ed.S. in counseling psychology and has more than 25 years of counseling and consultation experience with individuals, families and organizations. During her tenure with Preferred EAP, she has presented on numerous topics including stress management, communication, work-life balance, managing emotions, workplace conflict, and coping with change. Carolyn has a particular interest in holistic wellness and the benefits of meditation and exercise for the treatment of stress, anxiety and depression. Carolyn’s personal mission is to destigmatize mental and emotional health services and incorporate them into a more comprehensive plan for personal and corporate wellness.
Senior Vice President, Global Talent Acquisition, AmerisourceBergen
More Speaker Information Coming Soon
Sponsored & Moderated by Moderated by Marcia O’Connor, President & CEO, The O’Connor Group
Chief Revenue Officer, Philadelphia International Airport
Jim Tyrrell is the Chief Revenue Officer at PHL. He is responsible for business and real estate related functions, including the development, purchase, sale, use and lease of all Airport properties and facilities. He also oversees air service development, food, beverage and retail concessions, rental cars and other business development activities, including wireless internet access, Airport advertising contracts and all airline agreements. Additional responsibilities include commercial management and business development at Northeast Philadelphia Airport.
Previously Mr. Tyrrell served as the Deputy Director of Aviation, Property Management/Business Development, a position he was appointed to in 2001. He joined the Division of Aviation in 1987 and served as the Airport’s Property Manager from 1993-2001.
Mr. Tyrrell is a lifelong resident of Philadelphia and obtained his B.S. in marketing and management from Saint Joseph’s University in 1982. He serves on the Airports Council International-North America’s (ACI-NA) Air Cargo Committee and previously served on ACINA Commercial Management and Business Diversity committees. Currently, he is the 2016 Airport Revenue News Airport Property Manager of the Year.
CEO, Allegheny County Airport Authority
Christina Cassotis is CEO of the Allegheny County Airport Authority, operating Pittsburgh International Airport (PIT) and Allegheny County Airport (AGC).
Under Christina’s leadership, Pittsburgh International Airport has been transformed from a hub into a world-leading origin-and-destination airport with record growth. She has recruited multiple new domestic and international carriers, including passenger and cargo service. At the same time, Allegheny County Airport has experienced its own renaissance, capitalizing on the growth of private flying.
Christina has reshaped the long-term strategy for the region’s airports and is actively redefining what it means to be an airport. She has been a champion of keeping the organization’s vision at the heart of decision-making – to transform the airports to reflect and serve the community, inspire the industry, and advance the region’s role as a world leader.
Recognizing the travel experience begins long before passengers arrive at their destination, Christina believes airports are a critical piece of the journey. She is currently leading an ambitious billion-dollar construction project that will make PIT the first airport terminal in the U.S. to open post-pandemic, designed and constructed with the highest public health standards in mind.
The daughter of a pilot, Christina began her career in commercial aviation working for the Massachusetts Port Authority which operates Boston Logan International Airport. She went on to serve as Managing Officer for Airport Services for SH&E, leading a global team of aviation consultants.
Originally from New England, Christina holds a Master of Business Administration from the Massachusetts Institute of Technology Sloan School of Management and a Bachelor’s degree from the University of Massachusetts.
During her tenure, PIT was named Air Transport World’s Airport of the Year and Regional Airport of the Year by the CAPA Centre for Aviation.
In 2020, Fast Company magazine named PIT as One of the Most Innovative Companies in the World as well as a finalist in its World Changing Ideas awards.
Christina has received the Excellence in Visionary Leadership Award from Airports Council International – North America and has been named the Director of the Year for medium-size airports by Airport Revenue News.
She is a member of the board of directors for S&T Bancorp and the Federal Reserve Bank of Cleveland, Pittsburgh branch.
Sponsored & Moderated by Amanda Vining, President, Corporate Traveler
Chief Legal Officer, Chief Compliance Officer & Corporate Secretary, Aclaris Therapeutics
Kamil Ali-Jackson co-founded our company and has served as our Chief Legal Officer since 2012. Ms. Ali-Jackson also serves as our Chief Compliance Officer and Secretary. In addition, Ms. Ali-Jackson has served as the Chief Legal Officer of NST, LLC and NST Consulting, LLC since 2013 and 2014, respectively. From 2011 until its acquisition by Actelion US Holdings Company, a subsidiary of Actelion Ltd., in 2013, Ms. Ali-Jackson served as Chief Legal Officer, Chief Compliance Officer and Secretary of Ceptaris Therapeutics, Inc., a biotechnology company. From 2010 to 2011, she was a consultant to a private specialty pharmaceutical company. From 2006 to 2010, she served as General Counsel and Secretary of Ception Therapeutics, Inc., a biotechnology company that was acquired by Cephalon, Inc. Previously, Ms. Ali-Jackson served as legal counsel and a licensing business executive for a number of pharmaceutical companies, including Merck & Co., Inc., Dr. Reddy’s Laboratories Inc. and Endo Pharmaceuticals, Inc. Ms. Ali-Jackson received a J.D. degree from Harvard Law School and an A.B. degree in Politics from Princeton University. Ms. Ali-Jackson currently serves on the board of directors, audit committee, compensation committee and is the chair of the nominating and corporate governance committee of PDS Biotechnology Corporation, a publicly held company, and the board of trustees of Rosemont College, a private liberal arts college in Pennsylvania.
Executive Vice President, Human Resources, Incyte Corporation
Paula J. Swain joined Incyte in January 2002 and serves as Executive Vice President of Human Resources with additional responsibility for Facilities, Environment, Health & Safety & Internal Communications. Paula is also the Chair and Secretary of the Incyte Charitable Giving Foundation. Prior to joining the company, Paula spent nearly 10 years with DuPont Pharmaceuticals Company (acquired by Bristol-Myers Squibb Company in 2001) where she served as Vice President and Senior Vice President of Human Resources. She has also held human resource planning and employee relations positions with Chase Manhattan Bank, Marine Midland Bank and Delaware Trust Company. Paula received her B.A. in psychology from Rockhurst University and graduated from the strategic human resources planning program at Harvard Business School.
Paula is very involved in the Delaware Community and serves on several non-profit boards. She serves as the Member at Large for the Cancer Support Community Delaware, is the Secretary for The Committee of 100, and the Board Chair for Kind to Kids. She is a past member of the Executive Compensation & Succession Planning Committee of ChristianaCare and currently serves on the Council of Advisors. Paula also serves on the Board of Delaware Bio and is a member of the Board of Investors for the Wilmington Alliance and is on the Advisory Board of Fresh Start.
Senior Fellow and VP, Pharmaceutical Development, Product Development & Supply, GSK
More Speaker Information Coming Soon
Sponsored & Moderated by Moderated by Evjatar Cohen, Vice President, Global Life Sciences & Healthcare, Appian
Arthur Caplan, PhD
Mitty Professor of Bioethics, NYU Grossman School of Medicine
Arthur Caplan is currently the Drs. William F and Virginia Connolly Mitty Professor and founding head of the Division of Medical Ethics at NYU School of Medicine in New York City.
Prior to coming to NYU School of Medicine, Dr. Caplan was the Sidney D. Caplan Professor of Bioethics at the University of Pennsylvania Perelman School of Medicine in Philadelphia, where he created the Center for Bioethics and the Department of Medical Ethics. Caplan has also taught at the University of Minnesota, where he founded the Center for Biomedical Ethics, the University of Pittsburgh, and Columbia University. He received his PhD from Columbia University.
Dr. Caplan is the author or editor of thirty-five books and over 800 papers in peer reviewed journals. His most recent books are Vaccination Ethics and Policy, (MIT Press, 2017 with Jason Schwartz) and, Getting to Good: Research Integrity in Biomedicine Springer, 2018 with Barbara Redman).
He has served on a number of national and international committees including as the chair of the National Cancer Institute Biobanking Ethics Working Group, chair of the Advisory Committee to the United Nations on Human Cloning; chair of the Advisory Committee to the Department of Health and Human Services on Blood Safety and Availability. He has also served on the Presidential Advisory Committee on Gulf War Illnesses, the special advisory committee to the International Olympic Committee on genetics and gene therapy, the Special Advisory Panel to the National Institutes of Mental Health on Human Experimentation on Vulnerable Subjects, the Wellcome Trust Advisory Panel on Research in Humanitarian Crises, and the co-director of the Joint Council of Europe/United Nations Study on Trafficking in Organs and Body Parts. He is the co-founder and a member of the ge2p2 global foundation.
Caplan has served since 2015 as the chairperson of the Compassionate Use Advisory Committee (CompAC), an independent group of internationally recognized medical experts, bioethicists and patient representatives which advises Johnson & Johnson’s Janssen Pharmaceuticals about requests for compassionate use of some of its investigational medicines.
Dr. Caplan is a regular commentator on bioethics and health care issues for WebMD/Medscape, WGBH radio in Boston, WOR radio in New York City and CNN. He appears frequently as a guest and commentator on various other national and international media outlets.
Dr. Caplan is the recipient of many awards and honors including the McGovern Medal of the American Medical Writers Association and the Franklin Award from the City of Philadelphia. He was a USA Today 2001 “Person of the Year and was described as one of the ten most influential people in science by Discover magazine in 2008. He has also been honored as one of the fifty most influential people in American health care by Modern Health Care magazine, one of the ten most influential people in America in biotechnology by the National Journal, one of the ten most influential people in the ethics of biotechnology by the editors of Nature Biotechnology, and one of the 100 most influential people in biotechnology by Scientific American magazine.
During the Covid-19 pandemic, he co-directs an advisory group on sports and recreation for the US Conference of Mayors, created a working group on coronavirus vaccine challenge studies, developed an ethical framework for distributing drugs and vaccines for J&J, helped develop rationing policies for NYU LMC and many other health systems, is a member of the WHO advisory committee on Covid, ethics and experimental drugs/vaccines, helped set policy for WIRB/WCG for research studies He was an advisor to Moderna. And serves on the NCAA Sports and Covid committee.
He received the Patricia Price Browne Prize in Biomedical Ethics for 2011. In 2014 he was selected to receive the Public Service Award from the National Science Foundation/National Science Board, which honors individuals and groups that have made substantial contributions to increasing public understanding of science and engineering in the United States. In 2016 the National Organization for Rare Disorders (NORD) honored him with their Rare Impact Award and hFood and Drug Law Institute’s Distinguished Service Leadership Award. In 2019 he was honored by the Food and Drug Administration’s, Reagan/Udall Foundation with its Innovation Award.
He holds seven honorary degrees from colleges and medical schools.
Sponsored & Moderated by Erin Whaley, Partner, Health Sciences, Troutman Pepper
Executive Vice President, CIO Advisor for Healthcare, Zoom
Bill Shickolovich is the former Executive Vice President, Chief Information Officer of Wellforce Inc, a $2.1b Healthcare Provider Organization in Eastern Massachusetts. It is composed of several community hospitals, thousands of providers, and Tufts Medical Center, primary teaching affiliate of Tufts University.
Bill was the first CIO for Wellforce since its inception (2015) while also serving as the CIO at Tufts Medical Center for almost 19 years. Bill was responsible for defining the initial digital strategy for the newly formed health system. Prior to joining Tufts Medical Center, he worked in the Healthcare Information Technology Consulting practice of Ernst & Young LLP. Bill held a variety of positions in various capacities for 10 years at EY assisting clients achieve and implement their technology vision.
Prior to assuming the EVP, CIO of Wellforce, Bill served in a dual capacity of CIO and SVP of Operations at Tufts Medical Center, a $1b Academic Medical Center in downtown Boston. For several years he was responsible for Technology along with hospital operations transforming various aspects of care delivery and strategic initiatives.
Bill’s background includes extensive experience in working in all aspects of Healthcare Information Technology including strategic planning, technology operations, value-based care, outsourcing / managed services, technology evaluation, system selection, system implementation, system integration, and program management.
Bill has been a guest lecturer at Harvard School of Public Health, Leadership Strategies for Information Technology in Healthcare.
Bill is a 1989 graduate of Salem State University with a BS in Mathematics.
Bill is married to his wife Toni of 18 years. They have two boys – Walter and Sam. They reside in a small community north of Boston and thoroughly enjoy the many activities that come with raising two adolescent boys.
Covid has brought many opportunities to bring us closer together and explore where we live. We are lucky to live in a rural community and explored many hiking trails and biking paths. We had two fun outdoor family builds: a new treehouse and an expanded outdoor skating rink!
Sponsored by Newmark
President & CEO, Harmony Biosciences
Mr. Jacobs is President and Chief Executive Officer for Harmony Biosciences.
He joined Harmony from Teva Pharmaceuticals, where he held leadership roles as Senior Vice President and General Manager of the Respiratory Business Unit, Senior Vice President of Commercial Operations in North America and General Manager of Teva in Canada. Prior to joining Teva, he held positions of increasing scope and responsibility at major pharmaceutical companies, including Cephalon, Wyeth and Pfizer. Mr. Jacobs has over 25 years of commercial experience across multiple therapeutic areas, including CNS, Sleep Disorders, Pain Care and Respiratory, as well as rare disease and other specialty markets. His demonstrated expertise in developing market-leading commercial strategies, major product launches and building and leading highly effective teams and organizations has helped to shape Harmony’s positive culture of compassion for patients and passion for our business.
He holds a bachelor’s degree in business and a Master of Business Administration in marketing from the State University of New York.
President & CEO, University City Science Center
Tiffany brings more than 18 years of leadership transitioning innovative medical technologies from benchtop to bedside, building partnerships across academia, industry and economic development organizations.
She served as CEO of Global Center for Medical Innovation (GCMI), an Atlanta-based non-profit dedicated to supporting the development and commercialization of innovative medical products from 2011-2020. She led its startup phase, establishing a vision, building strategic relationships and convening key stakeholders across the medical device ecosystem. Wilson’s background in medical devices, commitment to fostering innovation and understanding of business strategies propelled her into a leadership role in the Southeast and brought her into the national spotlight. Wilson served on the National Advisory Council on Innovation and Entrepreneurship (NACIE) of the U.S. Department of Commerce, was recognized by Inc. Magazine as one of “17 Inspiring Women to Watch in 2017,” and one of Becker Hospital Review’s “110 Women in Medtech to Know in 2017.”
Managing Director, KPMG
Ross is a Managing Director in KPMG’s Business Tax Services practice. Ross focuses on tax planning and tax consulting, with a specific concentration in accounting methods, credits and incentives, and fixed assets for all sized companies in a wide range of industries. Ross is also the national co-leader for Federal Credits Services, including: Work Opportunity Tax Credit, Energy Credits, New Markets Tax Credit, Federal Disaster Tax Credits, Employee Retention Credit, and other emerging federal tax credits.
Senior Vice President & CFO, Idera Pharmaceuticals
John J. Kirby joined Idera Pharmaceuticals, Inc. in 2015 as Vice President of Corporate Accounting and has served as Vice President of Finance from July 2018 to July 2019 and as Senior Vice President and Chief Financial Officer since July 2019 (principal financial officer and principal accounting officer since October 2018). Prior to joining Idera, Mr. Kirby served as Assistant Controller at Endo Pharmaceuticals, Inc. from November 2014 to October 2015. From August 2012 to July 2014, Mr. Kirby served as Vice President, Chief Accounting Officer and Corporate Controller at ViroPharma Incorporated, which was acquired by Shire Plc in January 2014. Mr. Kirby began his career at KPMG, LLP in their Healthcare and Life Science Practice and served as a Regional Audit Director at AstraZeneca Pharmaceuticals L.P. prior to joining ViroPharma Incorporated. Mr. Kirby received his B.S. in Accountancy from Villanova University and is a licensed certified public accountant in the Commonwealth of Pennsylvania.
Founder & Managing Director, Danforth Advisors
Daniel is a proven leader of life science companies with more than 30 years of experience steering strategy, finance and operations across all stages of the corporate life cycle. As Co-Founder and Managing Director of Danforth Advisors, he leads a team of more than 100 consultants in strategic CFO advisory, accounting and operational support for over 200 clients, ranging from life science start-ups to publicly traded companies with $1 billion+ market capitalizations. He has served as CFO and executive-level advisor to numerous companies, including Apellis Pharmaceuticals, Cabaletta Bio, Cidara Therapeutics, Editas Medicine, Homology Medicines, Promedior, ProMIS Neurosciences and Stealth BioTherapeutics.
Consulting CFO, Danforth Advisors
Board Member, Public & Private Life Sciences Companies
Wendy is an experienced C-suite executive and corporate director with more than 30 years of experience serving both public and private life science companies. She has broad, practical leadership experience including financial and operational acumen as a CFO, COO and president. She has significant experience in mergers and acquisitions, global expansion, operations management, culture development, information technology systems and capital raise activities. She has held corporate leadership roles for Carmell Therapeutics, Centinel Spine, Camber Spine, Nuron Biotech and Globus Medical.
John Eppley, III, PE, PMP
FM Senior Director, Engineering, Tmunity
More Speaker Information Coming Soon
Senior Consultant, Med-Tex Services, Tmunity
Hoyt Emmons has over 30 year of EHS professional experiences include being the senior EHS Officer at over eight companies.
Hoyt has been recognized COVID-19 workplace subject matter expert (SME) and has provided COVID mitigation trainings for both Construction and General Industry and is an active member of six COVID-19 task teams. Hoyt has collaborated and developed COVID Health plans for the Philadelphia Building Trades, several universities, and numerous private companies. In addition, Hoyt acted as an advisor to the Philadelphia L&I Department relating to COVID mitigation practices at construction sites.
He is an adjunct professor of occupational safety at Temple University, teaches hospital Infectious Control Risk Assessment to the construction trades, is an OSHA Authorized Outreach Trainer for Construction and General Industry (OSHA 10- and 30-hour courses), is an instructor for the American Red Cross, and teaches Emergency Response courses ranging from the 8-hour introduction to the advanced 40-hour course.
Hoyt enjoys spending time with family and friends and he keeps busy as a professional sheep shearer, shearing over 2000 local sheep yearly at for over 200 flocks in PA and NJ.
President & CEO, J.N. Solutions
More Speaker Information Coming Soon
Executive Director, Human Resources, Harmony Biosciences
Ms. Murphy is the Head of Human Resources at Harmony Biosciences. She is responsible for leading Harmony’s Human Resources team and the design and execution of all HR programs, as well as championing the Harmony culture. Ms. Murphy brings to her role over 30 years’ experience in the pharmaceutical industry as a strategic HR business leader in both R&D and Commercial organizations in large, mid-size and startup environments. Previously, she has served as Director of Human Resources at Ironshore Pharmaceuticals, and as a global HR Business Leader in R&D at GlaxoSmithKline, where she provided strategic HR leadership to drive and navigate change, increase organizational capability, and develop and align talent to meet business performance goals. Prior to GSK, Audrey held HR positions of increasing scope and responsibility over 10 years at Nycomed Amersham, now GE Healthcare.
Ms. Murphy holds a bachelor’s degree in Industrial Psychology from Pennsylvania State University.
Karen E. Brophy
Chief Human Resources Officer, Optinose
Ms. Brophy is responsible for the strategic implementation of human resources programs and practices at Optinose. She has more than 30 years of HR experience across several diverse industries including biotechnology, pharmaceuticals and information management. Throughout her career, she has built and led HR teams while guiding companies through many types of organizational change.
Ms. Brophy grew her career by holding diverse positions of increasing responsibility at Dun & Bradstreet, Aventis and Celgene. Her career includes deep areas of focus across all disciplines within HR. At Dendreon, she held her first CHRO role, leading the organization through a period of intense change. Immediately prior to joining Optinose, she was VP of Human Resources at Agilex Fragrances.
Ms. Brophy holds a Bachelor of Arts in international relations from Mount Holyoke College.
Radius Health, Inc.
More Speaker Information Coming Soon